Anti-Müllerian hormone (AMH) has proven to be one of the most significant new markers in reproductive endocrinology in the last 10 years. The new Access AMH assay brings automation and convenience to Beckman Coulter’s established AMH tests, which include the AMH Gen II ELISA assay and the Immunotech EIA AMH/MIS assay. Access AMH is the only automated assay having excellent correlation to AMH Gen II, providing laboratories and physicians with convenient results that are consistent with current test values and published literature. Access AMH improves test accuracy by combining the proven AMH Gen II antibodies with calibrators using recombinant human AMH to provide a direct comparison to human patient samples. Assay features include convenient transition to automated testing through consistent and standardized results with Beckman Coulter’s AMH Gen II assay; improved support of fertility assessment through increased sensitivity and precision at the low end of the analytical measuring range; improved accuracy of patient results from calibrators prepared with recombinant human AMH; efficient and cost-effective results with less technician handling time and increased ease of use compared to manual assays; speed and flexibility through fully automated instrumentation; increased stability from lyophilized calibrators. The Access AMH assay has obtained CE marking and is now available on Beckman Coulter’s Access 2 immunoassay system in Europe and other select markets. The assay will be available on all Beckman Coulter immunoassay systems in Q4 of 2014. Beckman Coulter will continue to offer the AMH Gen II and IOT AMH assays along with its new automated AMH assay.
Read more

Serum creatinine measurement is a critical data in the glomerular filtration rate estimation (eGFR). However, traditional picrate alkaline method (Jaffé) suffers from well-known interferences from other serum components. A common approach is to compensate the measured value according to experimental data but this strategy presumes that those interferences are constant in value among samples, thus leading to inaccurate results in a clear oversimplification. Enzymatic methods, on the other hand, are more specific to creatinine measurement as they are free from those interferences, and are therefore a more suitable method for the purpose of eGFR, and as such are recommended by the scientific community. BioSystems introduces this method in its portfolio for both manual and automated systems (applications available on request). The reagent is free from interferences of lipemia, hemolysis, bilirubin or ascorbic acids and can be used with serum, plasma and urine samples.

Read more

A POC acute care analyser for the management of patients with cardiovascular disease symptoms, the Stratus CS 200 Acute Care Diagnostic System is designed to enhance simple operation and instrument management at the point of care to help facilitate rapid decision making and optimal patient care. The analyser has a user-friendly, touch screen interface that makes it easy to navigate through menus. A barcode reader eliminates the need for manual entry and reduces potential for error. The system also offers bi-directional connectivity, which allows for safe and secure results transmission with third-party data managers, and provides capability for remote operator lock-out and monitoring of calibration dates. In addition, the Stratus CS 200 system automatically spins whole blood into plasma for testing, reducing the risk of biohazard exposure and ensures results will be comparable to lab tests run on plasma samples. The Stratus CS 200 system delivers a robust cardiac assay menu, including high-sensitivity Troponin I. First results are available in as fast as 14 minutes, and subsequent results available in as little as four minutes. Cardiovascular diseases (CVDs) are the number one cause of death globally. According to the World Health Organization (WHO), in 2008, an estimated 17.3 million people died from CVDs, representing 30 percent of all global deaths. This number is expected to grow to 25 million by 2030. For patients with CVD, it is critical that their acute care be timely, safe and effective.

Read more

With the ability to connect up to three DxH 800 analysers with one DxH Slidemaker Stainer, the UniCel DxH Workcell enables labs to create a customized, scalable workflow solution that can streamline workflow management while delivering comprehensive and accurate patient results. Performance, low review rates and first past accuracy are all driven by Beckman Coulter’s exclusive Automated Intelligent Morphology (AIM), a multidimensional, flow cytometric technology that improves analysis of abnormal specimens, Digital Signal Processing (DSP), Multi-Transducer Module (MTM) and advanced algorithms. Workflow is managed efficiently through the DxH Workcell’s automated sample routing and increased data management capabilities. The UniCel DxH eliminates the need for pre-sort and offers workflow enhancements with bi-directional transport, preventing any potential for delay in sample testing and the reporting of results. The UniCel DxH Workcell is currently not available in the U.S. for in vitro diagnostic use.

Read more